This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Haemonetics (HAE) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic Displays All-Business-Line Growth Despite Cost Woes
by Zacks Equity Research
Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
Neogen's (NEOG) Food Safety Test Receives AOAC Clearance
by Zacks Equity Research
Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.
Bio-Rad's Blood Typing Market Growth Strong on New Products
by Zacks Equity Research
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.
Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients
by Zacks Equity Research
Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.
Walgreens, UnitedHealthcare Team Up to Boost Medicare Services
by Zacks Equity Research
Walgreens (WBA) partners with UnitedHealthcare to further strengthen the Medicare coverage for its customers.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
NuVasive Gets FDA Nod for CoRoent Small Interlock System
by Zacks Equity Research
NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
Henry Schein to Showcase New Dental Offerings at GNYDM
by Zacks Equity Research
Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.
Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
by Zacks Equity Research
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Dexcom (DXCM) gains from several positive developments.
Myriad Genetics' Test Added in Disease Activity Measure List
by Zacks Equity Research
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
Hologic (HOLX) Set to Divest Medical Aesthetics Business
by Zacks Equity Research
Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.
Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge
by Zacks Equity Research
The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
by Zacks Equity Research
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
Option Care is the Preferred Provider of Haemophilia Treatment
by Zacks Equity Research
Option Care Health (BIOS) can currently access all hemophilia factor treatments.
Here's Why You Should Hold GNC Holdings (GNC) Stock for Now
by Zacks Equity Research
Investors can still retain GNC Holdings (GNC) in their portfolio, thanks to solid prospects.
Safety Notice Issued by Boston Scientific (BSX) for AngioJet
by Zacks Equity Research
Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.